Skip to main content
. Author manuscript; available in PMC: 2020 Dec 14.
Published in final edited form as: Circulation. 2019 Mar 17;140(11):e596–e646. doi: 10.1161/CIR.0000000000000678

Figure 2. Treatment of T2DM for primary prevention of cardiovascular disease.

Figure 2.

CVD indicates cardiovascular disease; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, hemoglobin A1c; SGLT-2, sodium-glucose cotransporter 2; and T2DM, type 2 diabetes mellitus.